
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1407606
This article is part of the Research TopicOptimizing Radiotherapy for Cervical Cancer Efficacy Toxicity and Brachytherapy IntegrationView all 5 articles
The final, formatted version of the article will be published soon.
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective This study aims to explore the influence of intrafraction DNA damage repair on biologically effective dose (BED) in Ir-192 high-dose-rate (HDR) brachytherapy (BT) for cervical cancer. Specifically, we aim to comprehensively investigate the BED variations triggered by source decay at diverse treatment time points across different tumor cell lines and normal tissues.Methods Instead of the simplified BED (BED) formula, which fails to account for intrafraction and interfraction repair as well as repopulation, we utilized the full-form BED (BEDg) formula.Subsequently, BED values for various subtypes of cervical cancer tissues and Organs at Risk (OARs) were calculated by applying both BED formulas throughout a source exchange cycle.The findings reveal that the BEDg values are notably smaller and exhibit a significant decrease as the source activity decays and the treatment time extends, in contrast to the BED values. Regarding the tumor, when α/β = 10, the maximum changes in BED (∆BED = BED -BEDg) amounted to 3.05±0.47% in D 90% of High-Risk Clinical Tumor Volume (HRCTV) in BT. Upon considering the subtypes of cervical cancer tissues, the three largest ∆BED (%) are determined to be 14.06±1.67, 9.92±1.19, and 7.57±1.05 in D 90% of HRCTV for α/β = 10 (stage I and II cervix carcinoma), α/β = 16.46 (HX156c), α/β = 11.40 (HX155c). Analogous results are also detected in OARs.As the source decays, the maximum ∆BED(%) ( α/β = 3) at D 0.1cc of the bladder, rectum, sigmoid, and small intestine reached 13.37±2.27, 11.92±2.10, 12.45±2.27, and 11.91±2.62, respectively. Conclusions This study validates that source decay has a substantial impact on the BED of cervical cancer tissues with distinct cell lines and normal tissues. Through the comparison between the full-form BED formula and the simplified one, it is evident that the latter has a tendency to overestimate the BED value, particularly when the source activity is 2 Ci.
Keywords: High-dose-rate brachytherapy (HDR BT), cervical cancer, Source Decay Impact, Tumor cell lines, Intrafraction Damage Repair, Biological Effective Dose (BED) Frontiers
Received: 26 Mar 2024; Accepted: 08 Apr 2025.
Copyright: © 2025 Bi, Zhou, Xu and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhitao Dai, Department of Radiation Therapy, Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supplementary Material
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.